Autoimmunity BioSolutions (ABS) is pioneering a personalized, genetically guided immuno-corrective therapy designed to normalize or 'correct' elevated levels of soluble IL7 receptor (sIL7R), a fundamental driver of poor therapeutic response in autoimmune disease. This therapy targets a genetically defined subpopulation of autoimmune disease patients marked by a highly prevalent genetic variant (SNP) that elevates the expression of sIL7R and is associated with greater severity of disease, increased progression of disease, and poor response to current treatments. This immuno-corrective approach of targeting sIL7R in a genetic population is highly differentiated from current standards of care that rely on immunosuppressive mechanisms and has broad potential to enhance response to standards of care in the refractory population with elevated sIL7R across numerous autoimmune diseases.

Key Contact

Funding Events

Date	Amount	Type	Investors	Valuation
05/13/26	$1,000,000	Seed	Eos BioInnovation	undisclosed